Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Median effective dose of oliceridine + propofol for bronchoscopy sedation in ICU adults
ChiCTR2600123038Phase 4Not yet recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of oliceridine in postoperative pain (2 arms), sponsored by Tianjin Medical University General Hospital. Primary endpoint: Median effective dose of oliceridine combined with propofol for inhibiting responses to fiberoptic bronchoscopy in ICU young and elderly patients. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
oliceridine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR2600123038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123038.